CVRx supports symposium with focus on heart failure treatment advances

CVRx supports symposium with focus on heart failure treatment advances
CVRx brings Barostim to Kansas City

CVRx is actively participating in the Kansas City Heart Rhythm Society Symposium this weekend, emphasizing its commitment to advancing care for heart failure patients.

The company is highlighting Barostim, its device therapy designed to improve quality of life for individuals affected by heart failure, and inviting attendees to visit its booth for more information. Barostim has attracted attention in the medical device sector due to its novel approach in treating patients who do not respond well to conventional therapies.

CVRx executive Philip Adamson previously discussed the progression of heart failure treatments during a medical podcast appearance. The company recently completed its sixth Barostim implant at The Mount Sinai Hospital, reflecting continued procedural activity tied to the device’s adoption at the institution. These developments mark ongoing efforts to expand Barostim as a therapy option for heart failure patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.